CRISPR Therapeutics AG Insider Trading
Every director, officer and 10% holder of CRISPR Therapeutics AG has to report each trade in its stock within two business days of making it. This is those filings.
CRSP on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| James R. KasingerGeneral Counsel and Secretary2026-10-062K shat $60.04 | Sale10b5-1 plan | $119.5K |
| James R. KasingerGeneral Counsel and Secretary2026-09-2210.4K shat $60.24 | Sale10b5-1 plan | $626.5K |
| Ali BehbahaniDirector2026-09-1713.7K shat $57.09 | Sale | $780.9K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on CRSP
Follow CRISPR Therapeutics AG (CRSP) by email
New trades in CRISPR Therapeutics AG (CRSP) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.